Anti-LPD6B/ LYPD6B/ CT116 monoclonal antibody

Anti-LPD6B/ LYPD6B/ CT116 antibody for FACS & in-vivo assay

Target products collectionGo to LYPD6B/LYPD6B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0787-Ab-1/ GM-Tg-hg-MP0787-Ab-2Anti-Human LYPD6B monoclonal antibodyHuman
GM-Tg-rg-MP0787-Ab-1/ GM-Tg-rg-MP0787-Ab-2Anti-Rat LYPD6B monoclonal antibodyRat
GM-Tg-mg-MP0787-Ab-1/ GM-Tg-mg-MP0787-Ab-2Anti-Mouse LYPD6B monoclonal antibodyMouse
GM-Tg-cynog-MP0787-Ab-1/ GM-Tg-cynog-MP0787-Ab-2Anti-Cynomolgus/ Rhesus macaque LYPD6B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0787-Ab-1/ GM-Tg-felg-MP0787-Ab-2Anti-Feline LYPD6B monoclonal antibodyFeline
GM-Tg-cang-MP0787-Ab-1/ GM-Tg-cang-MP0787-Ab-2Anti-Canine LYPD6B monoclonal antibodyCanine
GM-Tg-bovg-MP0787-Ab-1/ GM-Tg-bovg-MP0787-Ab-2Anti-Bovine LYPD6B monoclonal antibodyBovine
GM-Tg-equg-MP0787-Ab-1/ GM-Tg-equg-MP0787-Ab-2Anti-Equine LYPD6B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0787-Ab-1/ GM-Tg-hg-MP0787-Ab-2; GM-Tg-rg-MP0787-Ab-1/ GM-Tg-rg-MP0787-Ab-2;
GM-Tg-mg-MP0787-Ab-1/ GM-Tg-mg-MP0787-Ab-2; GM-Tg-cynog-MP0787-Ab-1/ GM-Tg-cynog-MP0787-Ab-2;
GM-Tg-felg-MP0787-Ab-1/ GM-Tg-felg-MP0787-Ab-2; GM-Tg-cang-MP0787-Ab-1/ GM-Tg-cang-MP0787-Ab-2;
GM-Tg-bovg-MP0787-Ab-1/ GM-Tg-bovg-MP0787-Ab-2; GM-Tg-equg-MP0787-Ab-1/ GM-Tg-equg-MP0787-Ab-2
Products NameAnti-LYPD6B monoclonal antibody
Formatmab
Target NameLYPD6B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LYPD6B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LPD6B/ LYPD6B/ CT116 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0787
    Target NameLYPD6B
    Gene ID130576,71897,362133,693727,100686612,101084896,616612,100056459
    Gene Symbol and Synonyms2310010M24Rik,CT116,LYPD6B,LYPD7,RGD1562767
    Uniprot AccessionQ8NI32
    Uniprot Entry NameLPD6B_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000150556
    Target ClassificationN/A

    The target: LYPD6B, gene name: LYPD6B, also named as CT116, LYPD7. Enables acetylcholine receptor regulator activity. Predicted to be located in extracellular region and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.